» Articles » PMID: 31357143

Systemic Therapy for Brain Metastases

Overview
Specialty Hematology
Date 2019 Jul 30
PMID 31357143
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Metastases from cells outside of the central nervous system are the most common cancer found in the brain and are commonly associated with poor prognosis. Although cancer treatment is improving overall, central nervous system metastases are becoming more prevalent and require finesse to properly treat. Physicians must consider the biology of the primary tumor and the complex neurological environment that the metastasis resides in. This can be further complicated by the fact that the practice of cancer management is constantly evolving and therapy that works outside of the blood-brain barrier may not be effective inside of it. Therefore, this review seeks to update the reader on recent advancements made on the three most common sources of brain metastases: lung cancer, breast cancer, and melanoma. Each of these malignancies has been the subject of intriguing and novel avenues of therapy which are reviewed here.

Citing Articles

Prognostic Factors in Therapy Regimes of Breast Cancer Patients with Brain Metastases: A Retrospective Monocentric Analysis.

Curtaz C, Harms J, Schmitt C, Sauer S, Christner S, Kessler A Cancers (Basel). 2025; 17(2).

PMID: 39858042 PMC: 11763549. DOI: 10.3390/cancers17020261.


Neurosurgical resection of multiple brain metastases: outcomes, complications, and survival rates in a retrospective analysis.

Niedermeyer S, Schmutzer-Sondergeld M, Weller J, Katzendobler S, Kirchleitner S, Forbrig R J Neurooncol. 2024; 169(2):349-358.

PMID: 38904924 PMC: 11341644. DOI: 10.1007/s11060-024-04744-w.


Cell-cell communication characteristics in breast cancer metastasis.

Xu J, Gao F, Liu W, Guan X Cell Commun Signal. 2024; 22(1):55.

PMID: 38243240 PMC: 10799417. DOI: 10.1186/s12964-023-01418-4.


Compromised Blood-Brain Barrier Junctions Enhance Melanoma Cell Intercalation and Extravasation.

Saltarin F, Wegmuller A, Bejarano L, Ildiz E, Zwicky P, Vianin A Cancers (Basel). 2023; 15(20).

PMID: 37894438 PMC: 10605101. DOI: 10.3390/cancers15205071.


Factors Affecting 2-Year Survival in Patients With Non-Small Cell Lung Cancer Brain Metastases: Evidence from Indonesia's National Cancer Center, Jakarta, Indonesia.

Andriani R, Rosewitasari J, Hanif M, Mulawarman A, Kurniawati S, Fachri A Clin Med Insights Oncol. 2023; 17:11795549231178172.

PMID: 37359276 PMC: 10285584. DOI: 10.1177/11795549231178172.


References
1.
Twelves C, Souhami R, Harper P, Ash C, Spiro S, Earl H . The response of cerebral metastases in small cell lung cancer to systemic chemotherapy. Br J Cancer. 1990; 61(1):147-50. PMC: 1971312. DOI: 10.1038/bjc.1990.30. View

2.
Wu Y, Zhou C, Cheng Y, Lu S, Chen G, Huang C . Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol. 2012; 24(4):993-9. DOI: 10.1093/annonc/mds529. View

3.
Stewart D . A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neurooncol. 1994; 20(2):121-39. DOI: 10.1007/BF01052723. View

4.
Escriva-de-Romani S, Arumi M, Bellet M, Saura C . HER2-positive breast cancer: Current and new therapeutic strategies. Breast. 2018; 39:80-88. DOI: 10.1016/j.breast.2018.03.006. View

5.
Davies M, Saiag P, Robert C, Grob J, Flaherty K, Arance A . Dabrafenib plus trametinib in patients with BRAF-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017; 18(7):863-873. PMC: 5991615. DOI: 10.1016/S1470-2045(17)30429-1. View